Revolution Medicines, Inc.
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Revolution Medicines, Inc.
- Company name
- Revolution Medicines, Inc.
- Organisation type
- Industry
- Registered legal name
- REVOLUTION MEDICINES, INC.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- SEC filer number (CIK)
- 0001628171
- Legal Entity Identifier (LEI)
- 549300JU3X0LBCQ65892
Related records
Trials (24)
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer
- Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
- Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors